-
-
ISOPROTERENOL HCL (Generic for ISUPREL)
- QTY 1
- 0.2 MG/ML
- AMPUL
- Near 77381
ISOPROTERENOL (eye soe proe TER e nole) treats heart conditions such as slow heartbeat and heart block. It works by helping your heart beat stronger, making it easier for your heart to pump blood to the rest of the body. It may also be used to treat trouble breathing or wheezing (bronchospasm). It works by opening the airways of the lungs, making it easier to breathe.
Change Location
Set Price Drop Alert for:
ISOPROTERENOL HCL (Generic for ISUPREL)
- QTY 1
- 0.2 MG/ML
- AMPUL
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
ISOPROTERENOL HCL (Generic for ISUPREL)
- QTY 1
- 0.2 MG/ML
- AMPUL
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Change Form
Medicine Chest
ISOPROTERENOL HCL (Generic for ISUPREL) Lifestyle Interactions
-
Fluticasone Furoate 100mcg/1actuation, Inhalation powder
• Interaction: Grapefruit juice• Severity: Major• Notes for Consumers: Do not eat grapefruit or drink grapefruit juice while taking Fluticasone without talking to your doctor or healthcare professional. Side effects from Fluticasone may get worse. Call your doctor or healthcare professional as soon as possible if you have side effects like roundness of the face, high blood pressure, extreme irritability, fainting, stomach pain, or water retention.• Notes for Professionals: Instruct patients using inhaled fluticasone propionate products to avoid grapefruit juice. Patients using fluticasone furoate products should be aware of the potential for increased adverse effects if they regularly consume grapefruit juice. Increased systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression, may occur. Fluticasone is a CYP3A4 substrate; grapefruit juice is a strong CYP3A4 inhibitor. In drug interaction studies, coadministration with strong inhibitors increased plasma fluticasone propionate exposure resulting in 45% to 86% decreases in serum cortisol AUC. A strong inhibitor increased fluticasone furoate exposure by 1.33-fold with a 27% reduction in weighted mean serum cortisol; this change does not necessitate dose adjustment of fluticasone furoate.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
